Comparison 6. OnabotulinumtoxinA 64units versus OnabotulinumoxinA 40U one cycle of treatment, upper wrinkles.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
6.1 Participant assessment of success by analysing scores and scales	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
6.1.1 4 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
6.1.2 8 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
6.1.3 12 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
6.1.4 16 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
6.1.5 20 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
6.1.6 24 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
6.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
6.3 Physician assessment of success by analysing scores and scales	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
6.3.1 4 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
6.3.2 8 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
6.3.3 12 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
6.3.4 16 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
6.3.5 20 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
6.3.6 24 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
6.4 Total adverse events	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected